Alicia De Pablo

Dr. Alicia De Pablo


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Transplantation Reviews
Verified
Journal Article
Closed access
APAlicia De Pablo
Alicia De Pablo
FSF. Santos
F. Santos
ASA. Solé
A. Solé
JBJ.M. Borro
J.M. Borro
JCJ.M. Cifrian
J.M. Cifrian
FZF. Zurbano
F. Zurbano

1 July 2021 in Transplantation Proceedings
Verified
Journal Article
Closed access
APAlicia De Pablo
Alicia De Pablo
RARodrigo Alonso
Rodrigo Alonso
CCConstanza Ciriza
Constanza Ciriza
ELEloisa Lopez
Eloisa Lopez
FCFernando Canga
Fernando Canga
VPVirginia Perez
Virginia Perez

22 April 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
SRSara Remuzgo-Martínez
Sara Remuzgo-Martínez
FGFernanda Genre
Fernanda Genre
VCVerónics Pulito Cueto
Verónics Pulito Cueto
BABelén Atienza-Mateo
Belén Atienza-Mateo
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
Miguel Angel Gonzalez-GayMiguel Angel Gonzalez-Gay
Miguel Angel Gonzalez-Gay
The search for biomarkers that can help to establish an early diagnosis and prognosis of interstitial lung disease (ILD) is of potential interest. VEGF polymorphisms have been implicated in the development of several lung disorders. Consequently, we assessed, for the first time, the role of VEGF polymorphisms in the susceptibility and severity of ILD. A total of 436 Caucasian ILD patients (244 with idiopathic interstitial pneumonias (IIPs) and 192 with non-IIP) and 536 ethnically-matched healthy controls were genotyped for VEGF rs833061, rs1570360, rs2010963, rs3025020, and rs3025039 polymorphisms by TaqMan assays. Pulmonary function tests were collected from all the patients. VEGF serum levels were determined by ELISA in a subgroup of patients. No VEGF genotype, allele, carrier, or haplotype differences were found between ILD patients and controls as well as between IIP and non-IIP patients. However, an association of rs1570360 with IIP in women and also with lung function in IIP patients was found. None of the VEGF polymorphisms were associated with VEGF levels. In conclusion, our results suggest that VEGF does not seem to play a relevant role in ILD, although rs1570360 may influence the severity of ILD in women and a worse outcome in IIP patients.

1 July 2013 in Transplantation Proceedings
Verified
Journal Article
Closed access
APAlicia De Pablo
Alicia De Pablo
LJL. Juarros
L. Juarros
SJS. Jodra
S. Jodra
VPV. Pérez
V. Pérez
ELE. López
E. López
PGP. Gamez
P. Gamez

22 December 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
MGMARIA PIEDAD USSETTI GIL
MARIA PIEDAD USSETTI GIL
APAlicia De Pablo
Alicia De Pablo
DFDavid Iturbe Fernández
David Iturbe Fernández
RLRosalía Laporta
Rosalía Laporta
JCJosé Manuel Cifrián
José Manuel Cifrián
Background: The clinical benefits of the common off-label use of cytomegalovirus (CMV)-specific immunoglobulin (CMV-Ig) combined with antivirals in organ transplantation have not been previously assessed. The objective was to compare the risk of CMV infection and other post-transplantation outcomes between two CMV-Ig prophylaxis regimens in lung transplant recipients; Methods: Retrospective study of 124 donor CMV positive/recipient negative (D+/R–) patients receiving preventive ganciclovir/valganciclovir for 12 months, of whom 62 received adjunctive CMV-Ig as per label indication (short regimen [SR-Ig]; i.e., 7 doses over 2.5 months) and were compared to 62 who received an extended off-label regimen (ER-Ig) consisting of 17 doses over one year after transplantation. Results: The incidence of CMV infection or disease, acute rejection, chronic lung allograft dysfunction, and survival did not differ between the two CMV-Ig schedules. Although the time to the first CMV infection after transplantation was shorter in the ER-Ig than in the SR-Ig adjunctive group (log-rank: p = 0.002), the risk was independently predicted by antiviral cessation (odds ratio = 3.74; 95% confidence interval = 1.04–13.51; p = 0.030), whereas the CMV-Ig schedule had no effect. Conclusions: Extending the adjunctive CMV-Ig prophylaxis beyond the manufacturer’s recommendations up to one year does not confer additional clinical benefits regarding lung post-transplantation outcomes.

8 May 2024 in Life
Verified
Journal Article
Open access
PDF file
DIDavid Iturbe-Fernández
David Iturbe-Fernández
APAlicia De Pablo
Alicia De Pablo
VMVictor Manuel Mora-Cuesta
Victor Manuel Mora-Cuesta
RMRodrigo Alonso Moralejo
Rodrigo Alonso Moralejo
CLCARLOS ANDRES QUEZADA LOAIZA
CARLOS ANDRES QUEZADA LOAIZA
JCJosé Manuel Cifrián
José Manuel Cifrián
Our study aims to evaluate the effect of everolimus treatment on lung function in lung transplant (LT) patients with established chronic lung allograft dysfunction (CLAD). Methods: This retrospective study included LT patients in two reference LT units who started everolimus therapy to treat CLAD from October 2008 to October 2016. We assessed the variation in the maximum forced expiratory volume in the first second (FEV1) before and after the treatment. Results: Fifty-seven patients were included in this study. The variation in the FEV1 was −102.7 (149.6) mL/month before starting everolimus compared to −44.7 (109.6) mL/month within the first three months, +1.4 (63.5) mL/month until the sixth month, and −7.4 (46.2) mL/month until the twelfth month (p < 0.05). Glomerular filtrate remained unchanged after everolimus treatment [59.1 (17.5) mL/min per 1.73 m2 at baseline and 60.9 (19.6) mL/min per 1.73 m2, 57.7 (20.5) mL/min per 1.73 m2, and 57.3 (17.8) mL/min per 1.73 m2, at 1, 3, and 6 months, respectively] (p > 0.05). Everolimus was withdrawn in 22 (38.6%) patients. The median time to withdrawal was 14.1 (5.5–25.1) months. Conclusions: This study showed an improvement in FEV1 decline in patients with CLAD treated with everolimus. However, the drug was withdrawn in a high proportion of patients.